LaRose, M., Manji, G. A., & Bates, S. E. (2024). Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer. Seminars in Oncology, 51(1–2), 36–44. https://doi.org/10.1053/j.seminoncol.2023.11.001

Chan, E. M., Foster, K. J., & Bass, A. J. (2023). WRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI). Targeting the DNA Damage Response for Cancer Therapy, 313–328. https://doi.org/10.1007/978-3-031-30065-3_17

Aziz, Z., Wagner, S., Agyekum, A., Pumpalova, Y. S., Prest, M., Lim, F., Rustgi, S., Kastrinos, F., Grady, W. M., & Hur, C. (2023). Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened. JAMA Network Open, 6(11), e2343392. https://doi.org/10.1001/jamanetworkopen.2023.43392

In, G. K., Ribeiro, J. R., Yin, J., Xiu, J., Bustos, M. A., Ito, F., Chow, F., Zada, G., Hwang, L., Salama, A. K. S., Park, S. J., Moser, J. C., Darabi, S., Domingo-Musibay, E., Ascierto, M. L., Margolin, K., Lutzky, J., Gibney, G. T., Atkins, M. B., … VanderWalde, A. M. (2023). Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. Npj Precision Oncology, 7(1). https://doi.org/10.1038/s41698-023-00471-z

Yeh, C., Zhou, M., Bapodra, N., Hershman, D., Espinal, E., Moran, M., Rivero, M., Fojo, A. T., & Bates, S. E. (2023). Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials. Breast Cancer Research and Treatment, 204(1), 39–47. https://doi.org/10.1007/s10549-023-07131-7

Najjar, M., McCarron, J., Cliff, E. R. S., Berger, K., Steensma, D. P., Al Hadidi, S., Chakraborty, R., Goodman, A., Anto, E., Greene, T., Sborov, D., & Mohyuddin, G. R. (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Network Open, 6(11), e2342195. https://doi.org/10.1001/jamanetworkopen.2023.42195

Cuzzo, B., Lipsky, A., & Cherng, H.-J. J. (2023). Measurable Residual Disease Monitoring in Lymphoma. Current Hematologic Malignancy Reports, 18(6), 292–304. https://doi.org/10.1007/s11899-023-00715-6

Mejia Saldarriaga, M., Unkenholz, C., Fein, J. A., Monge, J., Rosenbaum, C., Pearse, R., Mapara, M., Inghirami, G., Lentzsch, S., Reshef, R., Niesvizky, R., & Bustoros, M. (2023). Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities. Blood, 142(Supplement 1), 3341–3341. https://doi.org/10.1182/blood-2023-187832

Gong, Z., Umoru, G., Monge, J., Shah, N., Mohyuddin, G. R., Radhakrishnan, S., Chakraborty, R., Schinke, C., D’Souza, A., & Mohan, M. (2023). Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study. Blood, 142(Supplement 1), 358–358. https://doi.org/10.1182/blood-2023-182695

Topping, R. P., Quill, T. A., Lamanna, N., & Sharman, J. P. (2023). Determining Clinical Practice Gaps for HCPs in Treating CLL Using CME-Based Surveys. Blood, 142(Supplement 1), 3716–3716. https://doi.org/10.1182/blood-2023-190329

Durot, E., Roos-Weil, D., Chauchet, A., Decroocq, J., Di Blasi, R., Gastinne, T., Bensader, H., Cheminant, M., Jacquet, C., Guidez, S., Gros, F.-X., Bachy, E., Cony-Makhoul, P., Treon, S. P., Delmer, A. J., Reshef, R., Le Gouill, S., Castillo, J. J., & Houot, R. (2023). CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study. Blood, 142(Supplement 1), 616–616. https://doi.org/10.1182/blood-2023-173988

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., Bowman, R. L., & Viny, A. D. (2023). Stag2-Cohesin Loss Attenuates Flt3 ITD Myeloid Blast Expansion Yet Preserves Mutant HSC. Blood, 142(Supplement 1), 2756–2756. https://doi.org/10.1182/blood-2023-190702

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., & Viny, A. D. (2023). Synergy of Stag2-Cohesin Loss Results in Expansion of Npm1c-Mutant Hematopoietic Stem and Progenitor Cells. Blood, 142(Supplement 1), 954–954. https://doi.org/10.1182/blood-2023-190627

Tashi, T., Hermine, O., Castells, M., Guilarte, M., Sabato, V., Maurer, M., Panse, J., Alvarez-Twose, I., Cabral, R., Bird, R., Barete, S., Bouillet, L., Hermans, M., Van Daele, P., González-De-Olano, D., Griffiths, E. A., Jurcic, J., Dybedal, I., Damaj, G. L., … Livideanu, C. B. (2023). Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial. Blood, 142(Supplement 1), 76–76. https://doi.org/10.1182/blood-2023-188904

Orlando, E. H., Gould, P., Cuzzo, B., Ford, M., Chen, Y., Sanjurjo, A., May, B., Tsapepas, D., Leeman-Neill, R. J., Bhagat, G., Dube, G., Morris, H., Arcasoy, S., Latif, F., Martinez, M., Pereira, M., Lipsky, A. H., Sawas, A., Reshef, R., … Amengual, J. E. (2023). The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder. Blood, 142(Supplement 1), 990–990. https://doi.org/10.1182/blood-2023-177823

Dhodapkar, M. V., Alsina, M., Berdeja, J. G., Patel, K. K., Richard, S., Vij, R., Leleu, X., Egan, D. N., Bergsagel, P. L., Reshef, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Eliason, L., Zhong, X., Greggio, C., Tran, S., … Siegel, D. S. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up. Blood, 142(Supplement 1), 2101–2101. https://doi.org/10.1182/blood-2023-173970

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 4316–4316. https://doi.org/10.1182/blood-2023-186376

Pazos, M., Estrella, B., Piorczynski, T. B., Tolu, S. S., Huang, W., Ryu, Y. K., & Amengual, J. E. (2023). First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL. Blood, 142(Supplement 1), 4184–4184. https://doi.org/10.1182/blood-2023-186639

Peters, D. T., Amburn, J., Tuchman, S., Lichtman, E. I., Jensen, C. E., Jain, K., Lentzsch, S., Chakraborty, R., Bhutani, D., & Rubinstein, S. M. (2023). Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance. Blood, 142(Supplement 1), 2027–2027. https://doi.org/10.1182/blood-2023-189341

Hanna, R., Frangoul, H., McKinney, C., Pineiro, L., Mapara, M., Dalal, J., Chang, K.-H., Jaskolka, M., Kim, K., Farrington, D. L., Wally, M., Mei, B., Lawal, A., Afonja, O. O., & Walters, M. C. (2023). AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia. Blood, 142(Supplement 1), 4996–4996. https://doi.org/10.1182/blood-2023-187397

Tolu, S. S., Piorczynski, T. B., Pazos, M., Estrella, B., Huang, W., Ryu, Y. K., Cherng, H.-J. J., Pro, B., & Amengual, J. E. (2023). JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity. Blood, 142(Supplement 1), 6118–6118. https://doi.org/10.1182/blood-2023-180875

Spyrou, N., Akahoshi, Y., Kowalyk, S., Morales, G., Beheshti, R., Aguayo-Hiraldo, P., Al Malki, M. M., Ayuk, F. A., Bader, P., Baez, J., Capellini, A., Choe, H., Defilipp, Z., Eder, M., Eng, G., Etra, A., Gleich, S., Grupp, S., Hexner, E., … Ferrara, J. L. M. (2023). A Day 14 Endpoint for Acute Gvhd Clinical Trials. Blood, 142(Supplement 1), 779–779. https://doi.org/10.1182/blood-2023-172955

Khatiwada, P., Soni, M., & Muranski, P. (2023). Highly Active Cytotoxic CD4 + T Cells Targeting EBV Oncoproteins with Enhanced In Vivo Anti-Tumor and Self-Renewal Properties. Blood, 142(Supplement 1), 3464–3464. https://doi.org/10.1182/blood-2023-190690

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718

Al Malki, M. M., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., Macbeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation. Blood, 142(Supplement 1), 2090–2090. https://doi.org/10.1182/blood-2023-187355

Fu, J., Li, S., MA, H., Brown, L. M., Mapara, M., & Lentzsch, S. (2023). Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling. Blood, 142(Supplement 1), 6610–6610. https://doi.org/10.1182/blood-2023-189820

Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D. J., Campbell, P., McKay, P., Leonard, J. P., Chen, Y., Chen, J., Bannerji, R., Kapopara, A., Szanto, A., & Morschhauser, F. (2023). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up. Blood, 142(Supplement 1), 3035–3035. https://doi.org/10.1182/blood-2023-179910

Tolu, S. S., Sanjurjo, A., Destephano, D., Pro, B., & Amengual, J. E. (2023). Outcomes in Minorities with PTCL By Clinical Trial Enrollment. Blood, 142(Supplement 1), 4431–4431. https://doi.org/10.1182/blood-2023-177722

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., Maly, J. J., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Bumma, N. (2023). Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study. Blood, 142(Supplement 1), 4746–4746. https://doi.org/10.1182/blood-2023-177968

Holtan, S. G., Martens, M. J., Al Malki, M. M., Efebera, Y., Kitko, C. L., Reshef, R., Rezvani, A. R., Shaffer, B. C., Solh, M. M., Yao, J. M., Runaas, L., Elmariah, H., Larkin, K. T., El Jurdi, N. H., Gooptu, M., Loren, A. W., Hall, A. C., Alousi, A., Jamy, O., … Bolanos-Meade, J. (2023). Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation. Blood, 142(Supplement 1), 897–897. https://doi.org/10.1182/blood-2023-187859

Proli, A., Sawas, A., Ho, G., Wang, J., & Fullerton, C. (2023). Methods for Identification of Blood Product Transfusions in a Cohort of Myelofibrosis Patients: An Assessment of Data Capture Using Insurance Claims and Electronic Health Record Abstraction. Blood, 142(Supplement 1), 7292–7292. https://doi.org/10.1182/blood-2023-189374

Midha, S., Gurumurthi, A., Costello, P., Redd, R. A., Freeman, C. L. L., Castaneda, O., Gonzalez, R., Ionescu, F., Gaballa, M., Kalariya, N., Khouri, J., Dima, D., Kocoglu, M. H., Sborov, D., Wagner, C. B., Atrash, S., Voorhees, P. M., Hashmi, H., Davis, J. A., … Patel, K. K. (2023). Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. Blood, 142(Supplement 1), 3499–3499. https://doi.org/10.1182/blood-2023-187565

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Viswabandya, A., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Dean, R., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T., Abaza, Y., Garcia, J. S., … Odenike, O. (2023). Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood, 142(Supplement 1), 3192–3192. https://doi.org/10.1182/blood-2023-174790

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival. Blood, 142(Supplement 1), 2013–2013. https://doi.org/10.1182/blood-2023-181905

Akahoshi, Y., Spyrou, N., Weber, D., Aguayo-Hiraldo, P., Ayuk, F. A., Bunworasate, U., Choe, H., Eder, M., Etra, A., Grupp, S., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Merli, P., Qayed, M., Reshef, R., Schechter-Finkelstein, T., Ullrich, E., … Nakamura, R. (2023). Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study. Blood, 142(Supplement 1), 776–776. https://doi.org/10.1182/blood-2023-181900

Muchtar, E., Sanchorawala, V., Hassan, H., Hegenbart, U., Schonland, S., Lee, H. C., Qazilbash, M. H., Kin, A., Houde, C. A., Buadi, F., Dispenzieri, A., Jacob, E. K., Arai, S., MD, M. C., Chakraborty, R., Lentzsch, S., Magen, H., Shkury, E., Sarubbi, C., … Gertz, M. A. (2023). The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients. Blood, 142(Supplement 1), 4784–4784. https://doi.org/10.1182/blood-2023-188115

Fahmy, L. M., Yang, H. R., Zhou, M., Beylergil, V., Schreidah, C. M., Bilgrami, Z., Kwinta, B. D., Schwartz, L., Fojo, A. T., Bates, S. E., & Geskin, L. J. (2023). Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis. Blood, 142(Supplement 1), 4443–4443. https://doi.org/10.1182/blood-2023-189493

Deluca, C., Beyer, M., Drew, H., Murray, J., Massey, J., Koffman, B., Battiato, K., Gribben, J. G., Lamanna, N., & Russomanno, C. (2023). The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia. Blood, 142(Supplement 1), 3715–3715. https://doi.org/10.1182/blood-2023-177959

Cherng, H.-J. J., Yang, X., Yancey, R., Gordillo, C. A., Piorczynski, T. B., Chan, H. T., Ofori, K. N., Bhagat, G., Califano, A., Pro, B., Booher, K., Amengual, J. E., Reshef, R., & Sina, A. A. I. (2023). Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes. Blood, 142(Supplement 1), 4371–4371. https://doi.org/10.1182/blood-2023-178376

Cicero, K. I., Dlamini, X., Mavengere, Y., Justman, J., Nuwagaba-Biribonwoha, H., Dlamini, M., Ngwenyama, S., Ngcamphalala, C., Low, A., Philip, N. M., El-Sadr, W. M., Sahabo, R., Abreha, T., Temesgen, S., Dlamini, S., Mahlalela, N., Chiuzan, C., Chen, Y., Pan, S. S., … Neugut, A. I. (2023). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African Population. Blood, 142(Supplement 1), 4767–4767. https://doi.org/10.1182/blood-2023-172435

Hoffman, J. E., Bumma, N., Richter, J., Dhodapkar, M. V., Lee, H. C., Suvannasankha, A., Houde, C. A., Maly, J. J., Shah, M. R., Baz, R., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Lentzsch, S., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Jagannath, S. (2023). Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment. Blood, 142(Supplement 1), 3359–3359. https://doi.org/10.1182/blood-2023-179170

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Peng, W., Lui, C., Wulff, J., … Jacobson, C. A. (2023). Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood, 142(Supplement 1), 4868–4868. https://doi.org/10.1182/blood-2023-174914

Hughes, M. S., Leng, S., Chakraborty, R., Bhutani, D., Mapara, M., Raza, S., & Lentzsch, S. (2023). Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up. Blood, 142(Supplement 1), 6576–6576. https://doi.org/10.1182/blood-2023-182842

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2023). Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM). Blood, 142(Supplement 1), 4768–4768. https://doi.org/10.1182/blood-2023-174908

Tolu, S. S., Gribbin, C., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A. A., Shore, T. B., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., & Ruan, J. (2023). Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL. Blood, 142(Supplement 1), 1698–1698. https://doi.org/10.1182/blood-2023-178231

DiPersio, J., Cooper, B. W., Suh, H. C., Koura, D., Bernard, L., Shah, N. N., Walter, R. B., Perales, M.-A., Mapara, M., Tamari, R., Loken, M. R., Breitschwerdt, K., Nath, S., Raffel, G. D., & Koehne, G. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood, 142(Supplement 1), 483–483. https://doi.org/10.1182/blood-2023-190037

Garcia-Manero, G., Odenike, O., Fleming, S., Roboz, G. J., Jacoby, M., Cunningham, I., Kreuzer, K.-A., Enjeti, A. K., Baer, M. R., Cook, R., Jurcic, J., Ku, G., Zhou, Y., Hoffman, D., Potluri, J., & Garcia, J. S. (2023). Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood, 142(Supplement 1), 1868–1868. https://doi.org/10.1182/blood-2023-187102

Muchtar, E., Palladini, G., Schonland, S., Dispenzieri, A., Wisniowski, B., Merlini, G., Milani, P., Hegenbart, U., Dittrich, T., Kastritis, E., Dimopoulos, M. A., Sanchorawala, V., Szalat, R. E., Liedtke, M., Gupta, M., Landau, H., Lentzsch, S., Hughes, M. S., Cibeira López, M. T., … Gertz, M. A. (2023). Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study. Blood, 142(Supplement 1), 3411–3411. https://doi.org/10.1182/blood-2023-190226

Shi, A., Ali, A. M., Cann, G., Shaknovich, R., Venn, O., Raza, A., & Liu, Q. (2023). Methylation Biology of a Blood-Based MDS Risk Stratification Test. Blood, 142(Supplement 1), 4599–4599. https://doi.org/10.1182/blood-2023-180256

Piorczynski, T. B., Ryu, Y. K., Pazos, M., Huang, W., Tolu, S. S., Estrella, B., & Amengual, J. E. (2023). Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 4391–4391. https://doi.org/10.1182/blood-2023-179271